You are here
Dr David Burgner
Professor David Burgner is a paediatric infectious diseases clinician scientist. He completed his PhD on susceptibility to severe malaria at Oxford University in the UK and subsequently trained at Great Ormond Street Hospital and St Mary's Hospital/Imperial College, London. He was the first and only infectious diseases paediatrician in Western Australia from 2002 until 2010, when he relocated to Melbourne to join the Murdoch Childrens Research Institute. He is currently a National Health and Medical Research Council (NHMRC) Senior Research Fellow, an honorary (NHFA) Future Leader Fellow, a Professorial Fellow at Melbourne University, and a paediatric infectious diseases consultant at Monash Children's Hospital.
- NHMRC Senior Research Fellow, Murdoch Childrens Research Institute
2014: National Health and Medical Research Council (NHMRC) Senior Research Fellowship level A
2014: NHFA (Honorary) Future Leader Fellowship
2010: Royal Australasian College of Physicians Excellence in Mentorship: Research and Academic
2009: NHMRC Clinical Career Development Fellowship (level 1)
2008: Australian Society for Infectious Diseases Frank Fenner Award for Advanced Research in Infectious Diseases
2006: European Society for Paediatric Infectious Diseases Scholarship
2005: Royal Australasian College of Physicians Servier Staff Fellowship
2002: Royal Australasian College of Physicians Covance Fellowship
2002: Raine Medical Research Foundation Research Award
1996: Medical Research Council Clinical Research Training Fellowship
The research Professor David Burgner leads addresses the relationships between communicable and non-communicable diseases, with particular emphasis on the role of early life inflammation and infection on the development of 'adult' diseases, including heart disease and obesity. The broad aim is to understand the basis for the markedly variable susceptibility to neonatal and paediatric infection and inflammation, and how these factors contribute to the development of subsequent risk for cardiovascular and metabolic disease. The group also has a particular interest in Kawasaki disease, a paediatric condition which may damage the coronary arteries and is the commonest cause of heart disease acquired in childhood.
The team employs a variety of approaches locally and through national and international collaborations. These include total population data linkage, population-representative cohort studies, cohorts of high-risk individuals and model systems, and molecular and genomic analyses.
- Early life determinants of cardiovascular risk: The Barwon Infant Study
- Distribution and determinants of large and small vessel vascular risk phenotypes in a population-representative paediatric cohort: The Longitudinal Study of Australian Children.
- Childhood infection and cardio-metabolic risk: The Cardiovascular Risk in Young Finns Study and The Western Australian population data resources
- Preterm infants, infection and innate immune responses
- Gestational age, birth weight and risk of severe infection in childhood
McCloskey K, Ponsonby AL, Carlin JB, Jachno K, Cheung M, Skilton MR, Koleff J, Vuillermin P, Burgner D; Barwon Infant Study investigator group. Reproducibility of aortic intima-media thickness in infants using edge-detection software and manual caliper measurements. Cardiovasc Ultrasound. 2014 Jun 3;12:18.
Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis. 2014 Aug;14(8):751-762.
Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, Jape G, Ramsay J, Kothari D, Cheng A, Burgner D. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133(4):e1009-14.
Levin M, Burgner D. Treatment of Kawasaki disease with anti-TNF antibodies. Lancet. 2014 May 17;383(9930):1700-3.
Howman RA, Charles AK, Jacques A, Doherty DA, Simmer K, Strunk T, Richmond PC, Cole CH, Burgner DP. Inflammatory and haematological markers in the maternal, umbilical cord and infant circulation in histological chorioamnionitis. PLoS One. 2012;7(12):e51836.
Khor CC, Davila S, Breunis WB, Lee Y-C, Shimizu C, Wright VJ, Yeung RSM, Tan DEK, Kar KS, Wang JJ, Wong TY, Pang J, Paul Mitchell P, Cimaz R, Dahdah N, Cheung YF, Huang GY, Yang W, Park I-S, Lee J-K, Wu J-Y, Levin M‡, Burns JC‡, Burgner D‡, Kuijpers TW‡, Hibberd ML‡ on behalf of the Hong Kong-Shanghai, Korean, Taiwan, U.S. and International, Kawasaki Disease Genetics Consortiums. Genome-wide association study identifies FCGR2A as a susceptibility factor for Kawasaki disease. Nature Genetics 2011 13;43(12):1241-6.
Strunk T, Doherty D, Jaques A, Simmer A, Richmond P, Kohan R, Currie A, Charles A, Burgner D. Histologic chorioamnionitis is associated with a reduced risk of late-onset sepsis in very preterm infants. Pediatrics 2012 Jan;129(1):e134-41.
Harnden A, Takahashi M, Burgner D. Kawasaki disease. Brit Med J. 2009;338:b1514.
Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright VJ, Thalamuthu A, Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, Hibberd ML. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 2009;5:e1000319.
Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev. 2009;22:370-385.
- Project grants
- Senior Research Fellowship
- Centre for Clinical Research Excellence
- Honorary Fellowship